ICS use by patients with COPD increases the risk of serious pneumonia. The risk is particularly elevated and dose related with fluticasone. While residual confounding cannot be ruled out, the results are consistent with those from recent randomised trials.
No takes yet. Share an insight, caveat, or question.
Suissa et al. (2013) studied this question.